— Event to be Webcast on Tuesday, October 17 at 11:00 a.m. ET —
DUBLIN, Oct. 10,
2023 /PRNewswire/ -- Mural Oncology plc, the
publicly-traded oncology company that Alkermes plc (Nasdaq: ALKS)
plans to establish in the fourth quarter of 2023 (Mural Oncology),
will hold an investor webcast during which members of Mural
Oncology's designated management team will provide an overview of
the company, its pipeline and strategy. The event will be webcast
live on Tuesday, Oct. 17, 2023, at
11:00 a.m. ET.
"We are excited for the opportunities ahead for Mural Oncology
and look forward to sharing an in-depth overview of our late-stage
clinical asset, nemvaleukin alfa, an investigational immunotherapy,
as well our preclinical pipeline candidates," said Dr. Caroline Loew, Chief Executive Officer designate
of Mural Oncology.
Dr. Loew will be joined by members of the Mural Oncology team
for a presentation followed by a question-and-answer session.
Alkermes expects to complete the separation of its oncology
business into Mural Oncology plc in the fourth quarter of 2023,
subject to customary conditions, including effectiveness of the
Form 10 registration statement for Mural Oncology plc, a favorable
opinion with respect to the tax-free nature of the separation, and
final approval of Alkermes' board of directors.
Investors are invited to listen to the live webcast, which can
be accessed on the Investors section of Alkermes' website at
www.alkermes.com or by dialing the U.S. toll free number + 1
866 400 0049, confirmation code 1830332. A replay of the webcast
will be available approximately two hours after the completion of
the event and may be accessed by visiting Alkermes' website.
Note Regarding Forward-Looking Statements
Certain
statements set forth in this press release constitute
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995, as amended, including,
but not limited to, statements concerning the anticipated status,
conditions to, and timing of completion of Alkermes' separation of
its oncology business. The company cautions that forward-looking
statements are inherently uncertain. The forward-looking statements
are neither promises nor guarantees and they are necessarily
subject to a high degree of uncertainty and risk. Actual
performance and results may differ materially from those expressed
or implied in the forward-looking statements due to various risks
and uncertainties. These risks and uncertainties include, among
others: unanticipated developments, costs or difficulties that may
delay or otherwise negatively affect the planned separation or the
completion thereof, including failure to satisfy or waive one or
more conditions of the separation on the planned timeline or at
all; and those risks and uncertainties described under the heading
"Risk Factors" in the company's Annual Report on Form 10-K for the
year ended Dec. 31, 2022 and in
subsequent filings made by the company with the U.S. Securities and
Exchange Commission (SEC), which are available on the SEC's website
at www.sec.gov. Existing and prospective investors are cautioned
not to place undue reliance on these forward-looking statements,
which speak only as of the date hereof. Except as required by law,
the company disclaims any intention or responsibility for updating
or revising any forward-looking statements contained in this press
release.
Mural Oncology Contact:
For Investors: Dave
Borah +1 781 299 8091
Alkermes Contacts:
For Investors: Sandy Coombs
+1 781 609 6377
For Media: Katie
Joyce +1 781 249 8927
View original
content:https://www.prnewswire.com/news-releases/mural-oncology-to-host-investor-webcast-on-october-17-301952752.html
SOURCE Alkermes plc